Abstract
Well into the 25th year of the HIV pandemics, and into the 15th year of the highly active antiretroviral therapy (HAART) era, liver transplantation (LT) in the HIV population might be viewed as both a problem and an opportunity. It is still a problem when we consider that only a small proportion of all HIV-infected patients with end stage liver disease (ESLD) will have access to this precious and limited resource. But, in the face of the continuous HAART refinements, that will probably expand in the future the pool of potential HIV- organ recipients, LT is also an opportunity. Considering the poor results observed in a subset of HIV/HCV coinfected patients with an ESLD in comparison to HCV monoinfected ones, LT is still a problem. But it is an opportunity if large and well designed clinical trials will reveal favorable prognostic factors associated to the subset of HIV/HCV coinfected patients that may undergo LT with satisfactory results.
Available data with good evidence presently support the practice of LT in HIV population. Thus, the issue is no longer “whether it is correct to transplant HIV-infected patients”, but “who are the patients that can be safely transplanted” and “when is the most correct timing to perform the surgical procedure”. Indeed, the benefits of LT in HIV-infected patients, especially in terms of mid- and long-term patient and graft survival, are strictly related to patient selection and correct timing for transplantation.
Aim of this article is to review some of the issues concerning HIV infection and LT, particularly with regard the opportunity of LT option in HIV setting and the most appropriate evaluation of an HIV-infected candidate for LT.
Keywords: Liver transplantation, HIV, HCV, HBV, selection criteria, survival benefit, HAART, liver disease, HIV/HCV coinfected patients
Current HIV Research
Title: HIV-Infected Patients and Liver Transplantation: Who, When and Why
Volume: 9 Issue: 2
Author(s): Marcello Tavio, Paolo Grossi, Umberto Baccarani, Luigia Scudeller, Federico Pea, Massimiliano Berretta, Gianluigi Adani, Marco Vivarelli, Alessandra Riva, Umberto Tirelli, Vittorio Bresadola, Pierluigi Viale and Andrea Risaliti
Affiliation:
Keywords: Liver transplantation, HIV, HCV, HBV, selection criteria, survival benefit, HAART, liver disease, HIV/HCV coinfected patients
Abstract: Well into the 25th year of the HIV pandemics, and into the 15th year of the highly active antiretroviral therapy (HAART) era, liver transplantation (LT) in the HIV population might be viewed as both a problem and an opportunity. It is still a problem when we consider that only a small proportion of all HIV-infected patients with end stage liver disease (ESLD) will have access to this precious and limited resource. But, in the face of the continuous HAART refinements, that will probably expand in the future the pool of potential HIV- organ recipients, LT is also an opportunity. Considering the poor results observed in a subset of HIV/HCV coinfected patients with an ESLD in comparison to HCV monoinfected ones, LT is still a problem. But it is an opportunity if large and well designed clinical trials will reveal favorable prognostic factors associated to the subset of HIV/HCV coinfected patients that may undergo LT with satisfactory results.
Available data with good evidence presently support the practice of LT in HIV population. Thus, the issue is no longer “whether it is correct to transplant HIV-infected patients”, but “who are the patients that can be safely transplanted” and “when is the most correct timing to perform the surgical procedure”. Indeed, the benefits of LT in HIV-infected patients, especially in terms of mid- and long-term patient and graft survival, are strictly related to patient selection and correct timing for transplantation.
Aim of this article is to review some of the issues concerning HIV infection and LT, particularly with regard the opportunity of LT option in HIV setting and the most appropriate evaluation of an HIV-infected candidate for LT.
Export Options
About this article
Cite this article as:
Tavio Marcello, Grossi Paolo, Baccarani Umberto, Scudeller Luigia, Pea Federico, Berretta Massimiliano, Adani Gianluigi, Vivarelli Marco, Riva Alessandra, Tirelli Umberto, Bresadola Vittorio, Viale Pierluigi and Risaliti Andrea, HIV-Infected Patients and Liver Transplantation: Who, When and Why, Current HIV Research 2011; 9 (2) . https://dx.doi.org/10.2174/157016211795569159
DOI https://dx.doi.org/10.2174/157016211795569159 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV Vaccine Development.
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strategies for the Synthesis of Mono- and Bis-Thionaphthoquinones
Current Organic Synthesis Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism Insertional Mutagenesis by Retroviral Vectors: Current Concepts and Methods of Analysis
Current Gene Therapy Nanomedicine Based Nanoparticles for Neurological Disorders
Current Medicinal Chemistry A Novel Information Theoretic Approach to Gene Selection for Cancer Classification Using Microarray Data
Current Bioinformatics Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Viral and Cellular Cytokines as Therapeutic Targets in AIDS-Related Lymphoproliferative Disorders
Current Drug Targets - Cardiovascular & Hematological Disorders Weighted Gene Co-expression Network Analysis Identifies Five Hub Genes Associated with Metastasis in Synovial Sarcoma
Combinatorial Chemistry & High Throughput Screening Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Regulatory Influence of Scaffolds on Cell Behavior: How Cells Decode Biomaterials
Current Pharmaceutical Biotechnology Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases
Current Protein & Peptide Science Membrane Fusion and Fission: Enveloped Viruses
Protein & Peptide Letters Management of Vaginal Cancer
Reviews on Recent Clinical Trials Chemotherapy with si-RNA and Anti-Cancer Drugs
Current Drug Delivery Bone-Targeted Doxorubicin-Loaded Nanoparticles as a Tool for the Treatment of Skeletal Metastases
Current Cancer Drug Targets Systemic Therapeutic Gene Delivery for Cancer: Crafting Paris Arrow
Current Gene Therapy